Month: September 2020

                                                                                                                                                           La FDA accorde la désignation de Breakthrough Therapy à Dupixent® (dupilumab) dans le traitement de l’œsophagite à éosinophilesUne désignation fondée sur les résultats positifs de la partie A d’un essai pivot de phase III.Dupixent est le premier et le seul médicament biologique ayant donné des résultats positifs cliniquement significatifs de phase III chez des patients âgés de 12 ans et plus souffrant d’œsophagite à éosinophiles.Aucun médicament n’est encore approuvé par la FDA pour le traitement de cette maladie inflammatoire de type 2 qui altère l’œsophage et la capacité des patients à déglutir et s’alimenter.Cette désignation conforte les opportunités de croissance de Dupixent dans...

PRESS RELEASE 14 September 2020, 07:00 CESTLarge Prospective Lung Cancer Study To Be Presented at ESMO Congress Shows Idylla™ Reduces EGFR Mutation Testing Turnaround Time by More than a Week, Allowing Faster Patient Management DecisionsMechelen, Belgium, 14 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that a large prospective lung cancer study1, co-supported by AstraZeneca, a global science-led biopharmaceutical company (LON: AZN), has been selected to be presented at the renowned European Society for Medical Oncology (‘ESMO’) Virtual Congress taking place between 19-21 September 2020. Rapid and accurate EGFR mutation testing is essential to make informed treatment decisions2 for patients with advanced non-small cell lung cancer...

PERSBERICHT 14 september 2020, 7:00 CESTGrote Prospectieve Longkanker Studie die wordt voorgesteld op het ESMO Congres toont aan dat Idylla™ de doorlooptijd van EGFR mutatie-testen met meer dan één week vermindert, hetgeen snellere beslissingen omtrent patiëntenbeheer toelaat Mechelen, België, 14 september 2020 – Biocartis Group NV (de ‘Vennootschap’ of ‘Biocartis’), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag aan dat een grote, prospectieve longkanker studie1, met steun van Astra Zeneca, een wetenschapsgedreven biofarmaceutisch bedrijf dat wereldwijd actief is (LON: AZN), werd geselecteerd om te worden voorgesteld op het gerenommeerde virtueel Congres van de European Society for Medical Oncology (‘ESMO’) dat plaatsvindt tussen 19 en 21 september 2020. Het snel en nauwkeurig testen...

Mrs. Stefanie Schmitz has informed the Supervisory Board and Board of Management of Corbion N.V. that for unforeseen personal health reasons she unfortunately had to decide to resign from the Supervisory Board with immediate effect.Stefanie Schmitz was appointed as member of the Supervisory Board at the Annual General Meeting of Shareholders on 29 June 2020.The Supervisory Board and the Board of Management fully respect her decision. Chairman of the Supervisory Board Mathieu Vrijsen said: “On behalf of the Supervisory Board, I would like to sincerely thank Stefanie Schmitz for her contribution to Corbion and I wish her all the best in her future endeavors.”Attachment20200914_ResignationSchmitz_ENG

Stefanie Schmitz heeft de Raad van Commissarissen en de Raad van Bestuur van Corbion N.V. geïnformeerd dat ze omwille van onvoorziene persoonlijke gezondheidsredenen helaas heeft moeten besluiten met onmiddellijke ingang terug te treden als lid van de Raad van Commissarissen.Stefanie Schmitz was benoemd tot lid van de Raad van Commissarissen tijdens de jaarlijkse Algemene Vergadering van Aandeelhouders op 29 juni 2020.De Raad van Commissarissen en de Raad van Bestuur respecteren haar besluit volledig. Voorzitter van de Raad van Commissarissen Mathieu Vrijsen zei: “Namens de Raad van Commissarissen wil ik Stefanie Schmitz oprecht danken voor haar bijdrage aan Corbion en wens haar het beste toe bij haar toekomstige activiteiten.”Bijlage20200914_ResignationSchmitz_NL

Vevey, September 14, 2020Nestlé commences tender offer for Aimmune Therapeutics, Inc.Société des Produits Nestlé S.A. (“Nestlé”) announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. (“Purchaser”), is commencing today a cash tender offer to purchase all of the outstanding shares of common stock of Aimmune Therapeutics, Inc. (Nasdaq: AIMT) (“Aimmune”) today for a price of USD 34.50 per share, net to the seller in cash, without interest and subject to any withholding taxes (the “Offer”). The Offer is being made upon the terms and subject to the conditions set forth in the Offer to Purchase (the “Offer to Purchase”), and related Letter of Transmittal and other related materials that will be filed by Nestlé and Purchaser with the United States Securities and Exchange Commission (the “SEC”) on September 14, 2020 (collectively, the...

In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1 In a key secondary endpoint, more than half of Beovu patients were maintained on a three-month dosing interval through year one, following the loading phase1 Beovu showed superior improvement versus aflibercept in change of central subfield thickness, a secondary endpoint, over the period of week 40 through week 521 Beovu demonstrated an overall well-tolerated safety profile comparable to aflibercept; in addition the rate of intraocular inflammation was equivalent between Beovu and aflibercept1 Novartis actively progressing full clinical development program of Beovu, with studies across wet AMD, DME, retinal vein occlusion and proliferative...

Paris, September 14, 2020, 7amPress releaseAB Science Presents Phase 2B/3 Study Results in Progressive Multiple Sclerosis at the World’s Largest Multiple Sclerosis Research Conference50% of patients suffering from multiple sclerosis have one of the progressive forms of the disease, for which there is no satisfactory treatment to date Masitinib, a tyrosine kinase inhibitor developed by AB Science, provides the first clinical evidence that targeting the innate immune system is an effective strategy for the treatment of progressive forms of multiple sclerosis.AB Science SA (Euronext – FR0010557264 – AB), a pharmaceutical company specialized on the research, development and commercialization of protein kinase inhibitors (PKIs), announced today that it has presented the world’s first key results from its Phase 2B/3...

Paris, 14 septembre 2020, 7h00Communiqué de PresseAB Science dévoile les résultats de son étude de Phase IIB/III dans les formes progressives de la Sclérose en Plaques à l’occasion du plus grand congrès international sur la sclérose en plaques50% des patients souffrant de Scléroses en Plaques sont atteints d’une des formes progressives de la maladie, pour lesquelles il n’existe aucun traitement satisfaisant à ce jour Le masitinib, l’inhibiteur de tyrosine kinase développé par AB Science, apporte pour la première fois la preuve clinique que cibler le système immunitaire inné est une stratégie efficace pour le traitement des formes progressives de la Sclérose en PlaquesAB Science SA (Euronext – FR0010557264 – AB), société pharmaceutique spécialisée dans la recherche, le développement et la commercialisation d’inhibiteurs de...

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) — African Gold Group, Inc. (TSX-V: AGG) (“AGG” or the “Company”) is pleased to announce that a 10,000 meter drill program has commenced at the Company`s flagship Kobada Gold Project in Southern Mali. The phase 3 program is designed to both increase resources through strike length extension drilling and upgrade certain inferred resources to indicated. The Company continues to focus on advancing the Kobada Gold Project, based upon delivery of its very robust Definitive Feasibility Study (“DFS”) in July 2020 at $1,530/oz gold.The 2020 work program will focus on the following:10,000 m drill program comprised of approximately 160 holes, utilising reverse circulation (RC) and diamond drilling (DD) rigs at the Kobada main shear zone, its northern extension and the Gosso target.Extension of main...